Summary of Product Characteristics (SmPC) - Adcal 1500 mg chewable tablets
1 NAME OF THE MEDICINAL PRODUCT
Adcal 1500mg Chewable Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Per tablet:
Calcium carbonate: 1500mg
equivalent to 600mg of elemental calcium
3 PHARMACEUTICAL FORM
Chewable Tablet
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Adcal is a chewable tablet recommended as a supplementary source of calcium when normal requirements are high and in the correction of calcium deficiency in the diet. They can be used in osteoporosis therapy as an adjunct to more specific conventional treatments. Adcal chewable tablets can be used as a phosphate binding agent in the management of renal failure.
4.2 Posology and method of administration
Oral.
Adults, elderly and children
Dietary deficiency and as an adjunct in osteoporosis therapy; 2 chewable tablets per day, preferably one tablet each morning and evening.
For use in binding phosphate in the management of renal failure in patients on renal dialysis, the dose should be adjusted for the individual patient and is dependent on the serum phosphate level.
The tablets should be chewed, not swallowed whole and taken just prior to, during or immediately following a meal.
4.3 Contraindications
Absolute contra-indications are hypercalcaemia resulting for example from myeloma, bone metastases or other malignant bone disease, sarcoidosis; primary hyperparathyroidism and vitamin D overdosage. Severe renal failure untreated by renal dialysis. Hypersensitivity to any of the tablet ingredients.
Relative contra-indications are osteoporosis due to prolonged immobilisation, renal stones, severe hypercalciuria.
4.4 Special warnings and precautions for use
Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully. Periodic checks of plasma calcium levels and urinary calcium excretion should be made in patients with mild to moderate renal failure or mild hypercalciuria.
Urinary calcium excretion should also be measured. In patients with a history of renal stones urinary calcium excretion should be measured to exclude hypercalciuria.
With long-term treatment it is advisable to monitor serum and urinary calcium levels and kidney function, and reduce or stop treatment temporarily if urinary calcium exceeds 7.5mmol/24 hours.
Allowances should be made for calcium and vitamin D supplements from other sources.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
The risk of hypercalcaemia should be considered in patients taking thiazide diuretics since these drugs can reduce urinary calcium excretion. Hypercalcaemia must be avoided in digitalised patients.
.
The effects of digitalis and other cardiac glycosides may be accentuated with the oral administration of calcium combined with Vitamin D. Strict medical supervision is needed and, if necessary monitoring of ECG and calcium.
Certain foods (e.g. those containing oxalic acid, phosphate or phytinic acid) may reduce the absorption of calcium
Calcium salts may reduce the absorption of thyroxine, bisphosphonates, sodium fluoride, quinolone and tetracycline antibiotics or iron. It is advisable to allow a minimum period of four hours before taking the calcium.
Calcium absorption is reduced in patients receiving systemic corticosteroid therapy. This should be taken in to account when patients are receiving concomitant therapy.
4.6 Fertility, Pregnancy and lactation
During pregnancy and lactation treatment with Adcal should be under the direction of a physician. During pregnancy and lactation, requirements for calcium are increased but in deciding on the required supplementation allowances should be made for availability of these agents from other sources. If Adcal and iron supplements are both required to be administered to the patient, they should be taken at different times (see Section 4.5).
4.7 Effects on ability to drive and use machines
None known
4.8 Undesirable effects
The use of calcium supplements has, rarely, given rise to mild gastro-intestinal disturbances, such as constipation, flatulence, nausea, gastric pain, diarrhoea.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard
4.9 Overdose
Overdosage may cause gastro-intestinal disturbances but would not be expected to cause hypercalcaemia except in patients treated with excessive doses of vitamin D. Treatment should be aimed at lowering serum calcium levels through a high fluid intake and low calcium diet.I In severe cases treatments with corticosteroid and other specialist treatment may be necessary. Alkalosis is a potential but rare risk.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Calcium carbonate is a well established medicinal material and is used extensively for supplementation in deficiency states. Calcium carbonate is also widely used as an antacid.
5.2 Pharmacokinetic properties
The pharmacokinetic profiles of calcium and its salts are well known. Calcium carbonate is converted to calcium chloride by gastric acid. Calcium is absorbed to the extent of about 15-25% from the gastro-intestinal tract while the remainder reverts to insoluble calcium carbonate and calcium stearate, and is excreted in the faeces.
5.3 Preclinical safety data
Calcium carbonate is a well known and widely used material and has been used in clinical practice for many years. As such toxicity is only likely to occur in chronic overdosage where hypercalcaemia could result.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Calcium carbonate is a well known and widely used material and has been used in clinical practice for many years. As such toxicity is only likely to occur in chronic overdosage where hypercalcaemia could result.
6.2 Incompatibilities
Not applicable, oral preparation.
6.3 Shelf life
24 months
6.4 Special precautions for storage
Do not store above 25°C.
Store in the original package. Keep container in the outer carton.
6.5 Nature and contents of container
PVC/PVdC aluminium foil blister packs of 10 (Physicians sample), or 112 tablets in a cardboard carton.
6.6 Special precautions for disposal
No special conditions
7 MARKETING AUTHORISATION HOLDER
Grünenthal Ltd
TOR Building
Saint Cloud Way
Maidenhead
Berkshire
SL6 8BN
United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 21727/0125
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
04/10/2005
10 DATE OF REVISION OF THE TEXT
10/07/2026